Tag: biotech outsourcing

Insights

Mastering CRO Selection in 2026: A Biotech’s Strategy for Lower Risk and Better Outcomes 

Insights by Rene Stephens, Managing Director, Danforth Advisors, a Danforth Health Company 

As we dive into 2026, the stakes for biotech development have never been higher, and a disciplined CRO selection strategy for biotechs has shifted from a competitive advantage to a survival requirement. Capital markets remain unpredictable, the pharma patent cliff continues to reshape partnership dynamics, and regulators are increasing scrutiny around vendor oversight, data integrity, and AI-enabled trial technologies. 

At the same time, CROs are navigating consolidation, capacity fluctuations, and geopolitical pressures, creating new execution risks even for well-prepared sponsors. In this environment, selecting the wrong CRO can derail entire programs, jeopardize valuation, and undermine investor confidence. That’s why more biotechs are partnering with outsourcing experts who bring data-driven frameworks, real-time market visibility, and negotiation power to one of the most consequential decisions in drug development. 

Why Engage Outsourcing Experts Now 

Navigate the Transformed CRO Landscape 

  • Assess rapidly consolidating global players and their post-M&A service quality 
  • Evaluate emerging regional CROs responding to geopolitical shifts and supply chain diversification 
  • Identify niche providers with specialized therapeutic expertise 
  • Distinguish CROs truly investing in AI/ML capabilities from those simply marketing them 
  • Track financially stable providers amid industry volatility 

Maximize Capital Efficiency (Still Non-Negotiable in 2026) 

  • Extract maximum value from every development dollar with follow-on funding still uncertain 
  • Leverage real-time CRO pricing intelligence as the market recalibrates 
  • Negotiate favorable terms despite limited leverage in a constrained vendor ecosystem 
  • Structure flexible payment terms aligned with funding milestones and runway 
  • Utilize creative deal structures (risk-sharing, milestone-based payments) as CROs compete for quality projects 

De-Risk in a Zero-Margin Environment 

  • Apply rigorous evaluation processes when the timeline slips or trial failures are unaffordable 
  • Identify red flags in operational capacity—resource constraints remain widespread 
  • Assess vendor financial stability as some CROs continue to face economic pressures 
  • Build contractual protections against geopolitical risk and supply chain disruptions 

Secure Strategic Contract Terms 

  • Performance accountability: SLAs with meaningful consequences for delays 
  • Financial protections: Milestone payments, earn-backs, and sponsor-friendly advance structures 
  • Flexibility: Clear change order processes to prevent scope creep 
  • Personnel commitments: Lock in key team members to avoid bait-and-switch scenarios 
  • Termination rights: Sponsor-favorable terms given the asymmetric risk profile 
  • Rate caps: Protection against inflation and arbitrary cost escalations 

Access Real-Time Market Intelligence 

  • Know which CROs are hungry for work vs. operating at capacity 
  • Track regulatory enforcement trends affecting timelines and budgets 
  • Navigate decentralized/hybrid trial models and supporting technologies 
  • Evaluate vendor experience with current FDA/EMA expectations and evolving guidances 

Optimize Internal Resources 

  • Free clinical operations teams to focus on execution rather than vendor management 
  • Avoid learning-curve mistakes that resource-constrained teams cannot afford 
  • Accelerate decision-making when speed-to-clinic determines competitive position 
  • Maintain objectivity and avoid legacy or relationship-based CRO decisions 

Leverage True Negotiating Power 

  • Benefit from outsourcing experts’ market volume and relationships 
  • Access pattern recognition from hundreds of CRO negotiations 
  • Reduce legal spend through streamlined expert-led negotiations 

A Modern CRO Selection Strategy for Biotechs Is No Longer Optional 

In a year defined by operational risk, regulatory pressure, and intense competition for high-quality vendors, having a rigorous CRO selection strategy for biotechs is essential. Small biotechs must execute flawlessly with limited capital and compressed timelines. 

You can’t afford to learn CRO selection through trial and error. 

Danforth Health’s seasoned experts can help you make selection and contracting decisions that protect your program, preserve your capital, and position you for success. Contact our team today.  

Insights

Talent Gaps & Layoffs in Biotech: Navigating the New Reality

Over the past two years, the biotech sector has weathered a difficult correction. Funding constraints and pipeline reprioritizations have led to waves of layoffs, creating leaner teams across the industry. Yet even as companies downsize, the need for specialized expertise has never been greater. The result is a widening talent gap – one that threatens productivity, continuity, and innovation.

Leaders at small and mid-sized biotech companies are being forced to make tough decisions: how to preserve institutional knowledge, sustain development momentum, and remain competitive with limited internal bandwidth.

Here are five takeaways for companies navigating this new workforce landscape:

1. Prioritize Core Expertise, Outsource the Rest

Not every role needs to be rebuilt internally. Identify which functions are critical to your intellectual property, regulatory strategy, or investor value story – and consider trusted external partners for everything else. Strategic outsourcing can allow you to execute on your business strategy while preventing burnout, reducing fixed costs, and ensuring continuity through development inflection points.

2. Reassess Organizational Design for Agility

Lean doesn’t have to mean overextended. Reassess how decisions have been made and consider if a smaller team could mean a more efficient approach, where bottlenecks exist, and which functions are duplicative. Flattening structures and empowering cross-functional project leads can help maintain momentum even with smaller teams.

3. Invest in Retention – Even When You’re Cutting Costs

After layoffs, there is often undesirable attrition, and the remaining team members often carry heavier workloads and higher stress. Retention depends on transparency, recognition, and growth opportunities. Simple actions, like reviewing and updating roles and responsibilities,  consistent communication about company direction, flexible work arrangements, or development stipends, can have an outsized impact on morale and loyalty.

4. Bridge Skill Gaps Through Partnerships and Interim Talent

Specialized expertise in areas like regulatory strategy, CMC, bioinformatics, and clinical operations is increasingly scarce. Interim or fractional experts can bridge capability gaps without the long-term cost of full-time hires, allowing your team to have the right level and amount of expertise as needed. If you are embracing a fractional model, look for experienced consultants or partner firms who understand biotech’s unique regulatory and operational nuances.

5. Revisit Workforce Planning Every Quarter

Embrace a just-in-time hiring model. While there is great talent in the market right now, hiring too far ahead of your needs can unnecessarily accelerate your cash burn. The market is shifting fast. What seemed essential six months ago may not be today. Building a rolling 3- to 6-month talent roadmap—aligned with your pipeline milestones and financing horizon—helps avoid reactionary hiring or deep cuts later on.

The Bottom Line

The biotech talent landscape is being reshaped in real time, but the need for great talent never goes away. In today’s environment, success will depend on strategic resourcing, organizational agility, and empathetic leadership. Companies that balance cost discipline with a thoughtful approach to people management will emerge stronger, more focused, and ready to capture opportunity as the market rebounds.

Danforth Health uniquely bridges both sides of the talent challenge — providing fractional experts to fill critical functional gaps. Our team can work with you to determine if a fractional resource is right for your business or if this is the time to invest in a full-time hire. Either way, we have the expertise and network to assess your needs, recruit the appropriate resources, and support their onboarding in a way that thoughtfully integrates them into your team quickly and efficiently.

Click here to schedule a free consultation about how we can support your talent needs.